Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687477 | 0.76 | THRB (0.40) | THRATHRBALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL17997112 | 0.74 | PRKDC (0.34) | ALDH1A1SMN1; SMN2LMNAHPGDHTT | |
| SCHEMBL16615600 | 0.72 | MEN1 (0.31) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16615508 | 0.71 | THRA (0.37) | THRATHRBALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL18089448 | 0.70 | ESR1 (0.45) | THRATHRBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18012155 | 0.69 | THRA (0.38) | THRATHRBALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16020870 | 0.69 | THRA (0.43) | THRATHRBALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16615507 | 0.68 | THRA (0.32) | THRATHRBALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13752652 | 0.68 | ERN1 (0.53) | ALDH1A1SMN1; SMN2LMNAS1PR2S1PR1 | |
| SCHEMBL11765947 | 0.68 | ALDH1A1 (0.63) | THRATHRBALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017106071-A1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2016187788-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016191239-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160228419-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015048363-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228419-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | NQO2, CYP3A5, QTRT1 | THRA 3454/4885THRB 3636/4885ALDH1A1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.